Accreditation, scope, and the question nobody asks PeptideMeter
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
The archive — 2025
Page 52 of 68 of this archive, newest first.
Suzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Shenzhen: 24 posters, one theme
Reported from the sessions, and from the two hours afterwards.
When a symptom is information and when it is noise
A dose held long enough stops being a pause and becomes a maintenance decision. That transition is rarely made explicitly.
Delayed emptying explains some of this, and not all of it
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
What changed at WXT in March, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A supplier suspends shipping to France after 4 consecutive customs detentions
The route did not close because of a rule about peptides.
The quiet end of the relabeller trading as Vantris Bio
A proper account of an operation that existed, and of what closing it cost.
Mexico declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
A design note on withdrawal trials, and why the run-in matters
The regain trajectories, arm by arm, with the estimands named.
How a correct calculation becomes a wrong dose
We have catalogued what readers report, ranked by the size of the dosing error each produces.
What changed at BCH in March, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Load, not cardio: the distinction the general advice keeps losing
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
A supplier suspends shipping to Germany after 21 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Janoshik result on a Changsha survodutide lot lands 1.0 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Two sessions a week, and the evidence behind the prescription
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
A year after stopping: what the trials found at the far end
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
A named analyst is the cheapest quality signal in this trade
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
From the floor in Chengdu: 9 posters, one theme
Reported from the sessions, and from the two hours afterwards.
South Korea health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The named comparison we promised two years ago
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.